Innovation in neurology patient management: Blood-based biomarkers and the role of Neurofilament Light Chain (NfL) in relapsing multiple sclerosis (RMS)

About this session

Intro: Dr. James Freeman (5 minutes)
Advancement of blood-based biomarkers in neurologic conditions (25 minutes)
Introduction of NfL as the first CE-marked (CE 0197) blood-based biomarker for RMS (25 min)
Extro: Dr. James Freeman (5 minutes)

Learning Objectives

Gain a comprehensive understanding of the current and future neurologic blood-based biomarkers.
Understanding the integration of NfL into laboratory practice and the clinic for RMS.

Henrik Zetterberg, MD, PhD

University of Gothenburg, University College London

Jean-Louis Bayart

Clinique St-Pierre, Ottignies, Cliniques Universitaires Saint-Luc

Vincent van Pesch, MD, PhD

Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain)